お知らせ • Jul 08
Nasdaq Stockholm Decides to Delist the Shares of Idogen from Nasdaq First North Growth Market On July 7, 2023, Idogen AB issued a with information that the Lund District Court had declared the company bankrupt. According to item 8.2.6 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist the financial instruments of an issuer if the issuer is subject of insolvency. With reference to the above, Nasdaq Stockholm AB has decided to delist the shares of Idogen AB from Nasdaq First North Growth Market with immediate effect. お知らせ • Nov 22
Idogen AB (publ) Appoints Jan Holgersson to Its Board of Directors Idogen AB (publ) announced that Jan Holgersson, who has served for several years as scientific adviser to the company, has agreed to strengthen the company’s Board of Directors in the role as co-opted Board member. Jan Holgersson is a professor of Transplant Immunology at Gothenburg University, the Medical Director of the Tissue Typing and Stem Cell Laboratories at Sahlgrenska University Hospital in Gothenburg, where he was also formerly the Head of Clinical Immunology and Transfusion Medicine. His research focuses on understanding the immunological mechanisms that underlie the rejection of transplanted organs and tissues. Another important initiative has been supporting the development of diagnostics for detection and semiquantification of antibodies against the ABH blood group antigens and other tissue antigens (non-HLA). Jan Holgersson is also Chairman of the Board of VERIGRAFT AB, a Swedish biotech company. Jan has been part of the company’s efforts at a detailed survey of the mechanisms of action for the company’s technology platform. Board Change • Nov 16
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Founder & Chairman of the Scientific Advisory Board Leif Salford is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. お知らせ • Nov 02
Idogen AB Announces Board Changes Idogen AB announced that Agneta Edberg has been elected as new Chairman of the Board since the current Chairman of the Board, Joakim Söderström, has requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company. In addition, Niklas Wallett, who was elected to the Board of Directors at the same time as Joakim Söderström, has also requested to resign from the Board of Directors at his own request. In September 2022, both Joakim Söderström and Niklas Wallett were elected to the Board of Directors of Idogen. Joakim Söderström was elected to be the Chairman of the Board, replacing Agneta Edberg. Joakim Söderström has now requested to resign from the Board of Directors at his own request as he has accepted a new position that is incompatible with being active in the Board of Directors of a public company and he will resume his role as a shareholder. In addition, Niklas Wallett has also requested to resign from the Board of Directors at his own request to resume his role as a shareholder. Due to the above changes, the Board of Directors of Idogen has elected Agneta Edberg as new Chairman of the Board, effective from today. As consequence of these changes, the Board of Directors consists of Agneta Edberg, Chairman, Sharon Longhurst and Christina Herder, meaning that the Board of Directors retains a quorum. Proposal for election of a new Board of Directors will be submitted by the Nomination Committee in connection with the announcement of the notice of the Annual General Meeting 2023, at the latest. お知らせ • Oct 15
Idogen AB (Publ) Announces First Patient Enters Idogen's Hemophilia Study Under the Ido 8 Program Idogen AB (publ) announced that the first patient has been included in the Phase I/IIa clinical trial with ItolDC-028, the company's cell therapy that is part of its IDO 8 program. The patient was included at Oslo University Hospital, where the trial will be carried out under the management of professor and chief physician Pål Andre Holme. The patients that will be included in the study all have hemophilia A and should have developed antibodies to their treatment with factor VIII. They should also have undergone unsuccessful immune tolerance induction (ITI) treatment and still have inhibitors against factor VIII. The patient who has been enrolled in Norway will now undergo planned tests ahead of the apheresis process, the purpose of which is to collect the patient's white blood cells which are then used to manufacture the cell therapy. The white blood cells will be sent to the company's partner, Radboud University Medical Center (RUMC) in the Netherlands, where they will be processed using the company's patented technology. The overall objective of the therapy is toinduce a tolerance to factor VIII, which in turn means the patient can once again undergo factor VIII treatment without any problems. 